Jensen Huang argues the "AI bubble" framing is too narrow. The real trend is a permanent shift from general-purpose to accelerated computing, driven by the end of Moore's Law. This shift powers not just chatbots, but multi-billion dollar AI applications in automotive, digital biology, and financial services.

A convergence of DNA sequencing, CRISPR, and AI allows scientists to move beyond just understanding biology to actively intervening. Medicine is now programming cellular behavior by rewriting DNA, representing a "step function" leap in what's achievable for treating disease at its root cause.

The next major AI breakthrough will come from applying generative models to complex systems beyond human language, such as biology. By treating biological processes as a unique "language," AI could discover novel therapeutics or research paths, leading to a "Move 37" moment in science.

The most significant breakthroughs will no longer come from traditional wet lab experiments alone. Instead, progress will be driven by the smarter application of AI and simulations, with future bioreactors being as much digital as they are physical.

Jensen Huang forecasts that the next major AI breakthrough will be in digital biology. He believes advances in multimodality, long context models, and synthetic data will converge to create a "ChatGPT moment," enabling the generation of novel proteins and chemicals.

The future of AI in drug discovery is shifting from merely speeding up existing processes to inventing novel therapeutics from scratch. The paradigm will move toward AI-designed drugs validated with minimal wet lab reliance, changing the key question from "How fast can AI help?" to "What can AI create?"

The next frontier in preclinical research involves feeding multi-omics and spatial data from complex 3D cell models into AI algorithms. This synergy will enable a crucial shift from merely observing biological phenomena to accurately predicting therapeutic outcomes and patient responses.

AI is reducing the cognitive overhead required to navigate biological knowledge, blurring the line between professional labs and motivated individuals. This trend actualizes Freeman Dyson's 2007 prediction that biotech, like computing, would become a decentralized, creative craft.

Patrick Collison believes we can finally cure complex diseases because biology now has a complete 'Turing loop': advanced sequencing to 'read' biological data, neural networks to 'think' about it, and CRISPR to 'write' changes by perturbing cells. This combination provides the necessary toolset for breakthroughs.